Karyopharm Therapeutics Inc
Clinical trials sponsored by Karyopharm Therapeutics Inc, explained in plain language.
Develops nuclear transport modulators for cancer treatment.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for myelofibrosis: selinexor trial targets spleen and symptoms Results expected Sep 2026 (estimated) May already have reported ↗
- New hope for lymphoma patients with no other options Results expected Dec 2026 (estimated) May already have reported ↗
- New pill combo aims to tackle tough lymphoma when other treatments fail Results expected Dec 2026 (estimated) 🚀 Make-or-break
- New drug cocktails aim to tackle tough myeloma Results expected Apr 2027 (estimated) May already have reported ↗
- New drug hope for myelofibrosis patients with low platelets Results expected Jun 2027 (estimated) May already have reported ↗
-
New drug cocktails aim to tackle tough myeloma
Disease control Recruiting nowThis study tests the drug selinexor in combination with various standard treatments for multiple myeloma, a type of blood cancer. It involves 300 participants with either relapsed/refractory or newly diagnosed disease. The goal is to find safe and effective doses and to see if th…
Phase 1/2 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Last-Resort cancer drug made available to patients before approval
Disease control Expanded accessThis program offers early access to the investigational drug selinexor for people with certain advanced cancers, such as multiple myeloma, lymphoma, sarcoma, and others, who have no other treatment options. Patients must not qualify for any ongoing clinical trial and must have ex…
Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug hope for myelofibrosis patients with low platelets
Disease control Recruiting nowThis Phase 2 trial tests the drug selinexor in people with myelofibrosis who have not taken JAK inhibitors and have low to normal platelet counts. The main goal is to see if selinexor can shrink the spleen by at least 35% after 24 weeks. Researchers will also check if it improves…
Phase 2 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for patients with advanced multiple myeloma: drug combo shows promise
Disease control Recruiting nowThis study tests a drug called selinexor combined with a low-dose steroid (dexamethasone) in people with multiple myeloma that has stopped responding to many other treatments. Some participants will also receive another drug, bortezomib. The goal is to see if these combinations c…
Phase 2 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC